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The role of natural killer (NK) cells in solid organ
transplantation is not well established, although several
recent reports highlight the importance of the activating
receptor NKG2D and its ligands in the development of
rejection during transplantation. The human NKG2D ligands
(MICA and MICB) are induced in allografts during acute and
chronic rejection, and the presence of anti-MICA antibodies is
correlated with a higher incidence of rejection. The binding
of these ligands to its receptor NKG2D activates NK cells,
enhances the functions of effectors, and allows NK cells to
function as a bridge between innate and adaptive immunity
associated with the transplantation. In fact, blockage of
NKG2D with the anti-NKG2Dmonoclonal antibodies prolongs
graft survival and prevents CD28-independent rejection in
heart and skin allograft mouse models. Furthermore, the
current immunosuppressive therapies can modulate the
expression of NK cell receptors and consequently the effector
functions of NK cells. That is particularly important during the
first few months after transplantation, when the
susceptibility to opportunistic viral infections is higher and
NKG2D has an essential role. In this review, we analyze in
detail the potential role of the NKG2D-activating receptor
and its ligands in the immune responses during the outcome
of solid organ transplantation. These findings open a new
pathway for therapeutic intervention that can contribute to
tolerance in solid organ transplantation.
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Natural killer (NK) cells, described by several groups in the
early 1970s, are important components of the innate immune
system and can kill target cells without a requirement for
a prior exposure to these targets, in contrast to cytolytic
T cells.1,2 These cells mediate their effector functions through
a complex integration of inhibitory and activating receptors
that interact with different ligands expressed on host cells.
Activated NK cells produce cytolytic molecules (perforin and
granzymes) that can directly kill allogeneic cells and
proinflammatory cytokines (tumour necrosis factor-a/b,
interferon (IFN)-g) that activate the adaptive immune
responses involved in the rejection.
The main inhibitory receptors, such as the killer Ig-like
receptors, leukocyte Ig-like inhibitory receptors, and the
C-type lectin receptor superfamily (CD94/NKG2A), recog-
nize self-MHC class I molecules that are expressed on healthy
cells and protect them from NK-induced lysis. In contrast,
the activating receptors bind mainly to stress-induced
molecules, or molecules found in pathological situations,
and lead to killing of target cells. The major activating NK
receptors in humans include the NKG2D, CD16, and the
natural cytotoxic receptors (NKp46, NKp44, and NKp30). A
great number of excellent reviews had been published
recently that describe the structure and function of NK-
related receptors.3
The ability of NK cells to recognize and kill allogeneic cells
without prior sensitization is explained by the concept of
‘missing self ’.4 Inhibitory receptors expressed on NK cells
interact with self-MHC class I molecules, deliver an
inhibitory signal, and lead to inhibition of NK activity. Thus,
target cells that lost major histocompatibility complex
(MHC) class I expression by virus infection or malignant
cell transformation become sensitive to NK cell destruction.
However, it is now known that the activation of NK cells
requires more than the absence of inhibitory signals, and
target cells have to express specific ligands for activating
receptors. The NKG2D-activating receptor recognizes several
ligands that are induced in response to cellular damage,
activate NK cell functions, and lead to the lysis of target cells.
In comparison with the missing self-hypothesis, this process
was called ‘induced or stressed’ self-hypothesis.
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During development, NK cells experience a process of
functional maturation referred to as ‘NK-cell education’ that
involves the interaction with self-MHC class I molecules via
inhibitory receptors. Two models have been proposed to
explain this process. The ‘licensing’ hypothesis postulates that
the engagement of MHC class I to inhibitory receptors on
NK cells during development allows these cells to become
competent effector cells.5 Although the ‘disarming’ model
suggests that the absence of MHC class I molecules on
normal cells would chronically stimulate NK cells and render
them anergic, recent studies demonstrated that the educa-
tional process of NK cells is regulated by the number and the
affinity of each inhibitory receptor for self-MHC class I
molecules.
During bone marrow transplantation, NK cells have a
major role in the rejection of donor bone marrow cells, but
the impact of donor and recipient NK cells in solid organ
allografts is a controversial point even today. First, studies
showed that heart transplants in Rag/ mice, which are
deficient in T and B cells, but maintain an intact NK cell
population, are accepted indefinitely and survive throughout
the length of the experiment, suggesting that NK cells are not
sufficient to reject a heart allograft. However, recent studies
highlight the ability of NK cells to promote graft injury or
rejection.6–9 The cellular microenvironment and the interac-
tions with other cells (dendritic cells (DCs), T and B cells)
may modulate the immune responses developed against the
donor and may contribute to these ambiguous effects of NK
cells. Furthermore, the functions of NK cells are determined
ultimately by integrated signals obtained from both inhibi-
tory and activating receptors, which are expressed in a
stochastic pattern. The inhibitory and activating receptor
profiles on NK cells aid in identifying the many subsets of NK
cells with different functional properties. Taken together, NK
cells may have some functional plasticity during transplanta-
tion, so that they can contribute to promoting rejection or
inducing tolerance on the basis of the surrounding milieu.
As we have previously reported, NKG2D is one of the
most potent activating receptors expressed on NK cells, and
induces a potent cytotoxic response in humans through its
association with the adaptor molecule DAP10 (ref. 10). The
interaction of NKG2D with its ligands has been involved in
multiple processes and has an important role in infections,
tumors, and autoimmune diseases. Recently, several studies
reported the contribution of NKG2D and its ligands in the
solid organ transplantation, and suggest a great potential for
therapeutic intervention of this interaction.
NKG2D LIGANDS IN SOLID ORGAN TRANSPLANTATION
The ligands of NKG2D in humans are MHC class I chain-
related A and B (MICA, MICB), and ULBP 1–5 (UL-16-
binding protein).11 Mice lack MIC genes but express the
ULBP homologous proteins, namely RAE-1, H60, and
MULT-1. MICA/B genes are encoded in the MHC region
and share 28–35% homology to human leukocyte antigen
class I genes. The MICA/B genes are highly polymorphic,
with more than 72 MICA and 31 MICB recognizable alleles
(http://www.ebi.ac.uk/imgt/hla).
The main findings have focused on the presence of anti-
MICA antibodies in patients with a kidney or heart
transplant and their direct involvement in the failure of the
allograft. The development of anti-MICA antibodies after
kidney transplantation is a significant risk factor in the
outcome of the graft, and is independent of the presence of
anti-HLA antibodies.12 Moreover, increased rates of allograft
failure in human leukocyte antigen-well-matched patients
were observed among those with antibodies against MICA
before transplantation.13 Our group has also described a high
correlation between the presence of anti-MICA antibodies
and increased risk of acute rejection during the first year after
heart transplantation.14 Because excellent reviews have been
published regarding the humoral response against MICA; this
article will focus on the cellular immune response.
NKG2D ligands are expressed at low levels in many
normal cells. Their expression is increased on stressed cells by
infection or malignant transformation, and it alerts the
immune system of adverse cellular conditions. Increased
MICA/B expression has been observed in several transplanted
grafts with histological evidence of rejection and/or cellular
injury14–16 (Table 1). Studies in animal models showed that
ischemia/reperfusion injury (IRI), which is caused after
transplantation, induces expression of RAE-1 on tubular
epithelial cells, permits the infiltration of NK cells inside the
graft, and increases the risk of acute allograft rejection
by NKG2D-dependent mechanisms.17,18 Furthermore, the
simultaneous expression of Rae-1, H60, and NKG2D during
acute heart allograft rejection support the role of this
interaction in the immune responses associated with
transplantation.19 Whether an analogous mechanism occurs
in humans still needs to be elucidated; however, it is known
that IRI leads to the activation of endothelial cells, which
increase their expression of adhesion molecules and recruit
effector cells into the tissue. Recently, hypoxia-inducible
factor-1 was shown to increase the MICA expression on
human renal tubular epithelial cells and cardiomyocytes
during the hypoxia/reoxygenation process that occurs during
IRI.20,21 These findings provide the first insights on the IRI
mechanisms that induce MICA expression, and can spur the
development of new strategies to reduce the early renal
inflammatory injury after transplantation.
One of the best known mechanisms of immune evasion in
tumor cells is the proteolytic release of MICA from the cell
surface. The endoplasmic reticulum protein 5 interacts with
MICA in the cell membrane and induces a conformational
change that is necessary for proteolytic cleavage of the
molecule. We identified a soluble form of MICA in the serum
samples, from heart transplant patients, obtained during the
first year after transplant.22 Transplant patients with high
levels of soluble MICA showed a lower incidence of acute
rejection and had higher graft function and survival. In vitro
studies demonstrated that soluble MICA engages NK cells
expressing NKG2D, induces receptor internalization and
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degradation, and impairs the NKG2D-mediated allogenic
cytolytic responses. This finding supports a new mechanism
by which NKG2D ligands could contribute to thwarting
allograft rejection, and elucidates its inhibition of effector
functions mediated by NK and CD8þ T-cytotoxic cells.
NKG2D MEDIATES ALLOGRAFT INJURY
The NKG2D-activating receptor is expressed in all NK cells,
gd T, ab CD8 T, and NKT cells.23 NKG2D functions as a
primary activating receptor in NK cells, and a co-stimulatory
receptor in CD8þ T cells. In these cells, a T-cell receptor-
mediated stimulus is necessary for activation, although,
under certain circumstances, NKG2D might be able to
function as an activating receptor, independent of T-cell
receptor stimulation.
Recently, studies in mouse models deficient in NKG2D
showed that this receptor is involved in the development,
homeostasis, and survival of NK cells. NK cells from NKG2D-
deficient mice show a higher proliferation rate of immature
NK cells and are more susceptible to apoptosis.24 NKG2D
signaling is also implicated in the effector functions of NKs as
these NKG2D/ NK cells showed a weaker cytolytic
response and lower IFN-g production against target cells
expressing NKG2D ligands.
The activation of NK cells through the NKG2D receptor
bound to its ligands may regulate multiple immunological
pathways involved in the rejection or the outcome of allograft
transplantation (Table 1). The best known example of the
NKG2D function is reported in bone marrow transplantation
of mice.25 NK cells reject the bone marrow cells expressing
the NKG2D ligand, Rae-1, and the blockade with a
neutralizing non-depleting NKG2D monoclonal antibody
prevents rejection. Similar results were obtained using a
mouse model with severe combined immunodeficiency
disease recipients bearing MHC class II-deficient skin
allografts.8 Transferred CD4 T cells, which recognize
alloantigens only through the indirect pathway, mediate
rejection by a NK cell-dependent route. Inflammation
induced by indirectly primed CD4þ T cells leads to the
upregulation of NKG2D ligands in the allografts. Concur-
rently, these CD4þ T cells recruit and trigger activation of
NK cells through the interactions of the NKG2D-activating
receptor with its ligands on donor cells. These results were
corroborated so that NKG2D blocking significantly pro-
longed survival but did not induce a permanent acceptance,
probably because of the involvement of other activating NK
receptors.
Only some indirect evidence has reported the involvement
of NK cells during rejection of kidney transplants. Accumu-
lation of CD56þ NK cells expressing granzyme in kidney
biopsies of patients undergoing acute rejection suggests a role
of their cytolytic activity in kidney allograft rejection.26
Table 1 | Effects of NKG2D and its ligands in solid organ transplantation
Transplant Animal model/samples Biological effects Reference
NKG2D
Heart CD28/ heart allotransplantation
model
Increase of NKG2D ligands within the graft amplify the adaptive immune
response and increase graft injury
Blockage of NKG2D prolongs the cardiac allograft survival
29
Skin SCID mice bearing MHC class II-
deficient skin allograft
Increased expression of NKG2D ligands on indirectly primed
CD4+ T cells in the rejecting grafts
Activation of NK cells through NKG2D leads to cytotoxicity against graft
cells and rejection
Blockage of NKG2D prolongs graft survival but does not induce permanent
graft acceptance
8
Kidney Human biopsies and urine Elevated levels of NKG2D mRNA and NKG2D+ cells in urine and kidney
biopsies, respectively, diagnosed with acute and chronic rejection
27
NKG2D ligands
Kidney TEC IRI induces the expression of NKG2D ligand, Rae-1, in TEC
NK cell engagement through NKG2D allows NK cell-induced apoptosis
17
Kidney Renal IRI mice model IRI increases the expression of Rae-1 and H60 and activates NK and
CD8+ T cells
18
Heart C57BL/6 heart allotransplant model Simultaneous increase of Rae-1, H60, and NKG2D during acute cardiac
allograft rejection
19
Kidney Human renal proximal tubular
epithelial cells (HK2 cell line)
Hypoxia during IRI increases MICA expression through a HIF-1 pathway
Enhance cytotoxicity and IFN-g secretion by NK cells, leading to graft injury
20
Kidney and
pancreas
Biopsies Increase of MICA/B in epithelial cells of kidney and pancreas allografts
during acute and chronic rejection
16
Kidney Biopsies Upregulation of MICB molecules following renal transplantation associated
with evidence of cellular stress
15
Heart Biopsies Increase of MICA in endomyocardial biopsies with histological evidence
of acute rejection
14
Abbreviations: HIF, hypoxia-inducible factor; IFN, interferon; IRI: ischemia/reperfusion injury; MHC, major histocompatibility complex; MICA, MHC class I chain-related A;
MICB, MHC class I chain-related B; NK, natural killer; SCID, severe combined immunodeficiecy disease; TEC, tubular epithelial cells.
54 Kidney International Supplements (2011) 1, 52–57
meet ing repor t B Sua´rez-A´lvarez et al.: NKG2D in solid organ rejection
Furthermore, IRI likely induces nonspecific recruitment of
NK cells via early graft infiltration.27 A recent study
associated the presence of NK cells with the mechanisms of
microcirculation injury during antibody-mediated rejection
in kidney transplants.9 They proposed that donor-specific
antibodies are able to bind to the endothelium and recruit
NK cells that produce IFN-g and trigger antibody-dependent
cellular cytotoxicity. The increased expression of NK-cell
transcripts, such as CX3CR1, indicated the recruitment of
NK cells to allograft endothelium when donor-specific
antibodies are present.
The NK-cell receptors that are directly involved in the
immune responses after kidney transplantation have not been
well defined, but various studies suggest that NKG2D could
have an important role. An elevated NKG2D mRNA
expression was correlated to severity of acute rejection, and
NKG2Dþ cells were detected in clusters around tubules in
biopsies derived from patients diagnosed with acute and
chronic rejection.28 NKG2D gene expression was also
detected in urinary sediments obtained at 2–3 days before
the acute rejection episode; these findings raise the possibility
that NKG2D may be able to serve as an additional
informative biomarker of transplantation outcome.
That is, the NKG2D activating receptor might participate
not only in the immune responses that occur initially after
transplantation and is promoted by IRI, but it may also
contribute to the development of acute rejection. However,
further studies are needed to elucidate whether the source
of NKG2D receptors is predominantly NK cells or CD8þ
T cells.
NKG2D RECEPTOR, A BRIGDE BETWEEN INNATE
AND ADAPTIVE IMMUNITY
Maier et al.7 were the first to demonstrate that although NK
cells may not be sufficient to directly reject a solid allograft,
they can participate in acute rejection by promoting the
actions of alloreactive T cells. They demonstrated that
CD28/ mice, which have an impaired T-cell co-stimula-
tion, reject fully MHC-mismatched allogeneic hearts in a
manner similar to CD28þ /þ recipients. However, CD28/
mice depleted of NK cells show significant prolongation of
allograft survival.
The bidirectional crosstalk between NK cells and DCs is
involved in the maturation of DCs and the activation of an
adaptive immune response. DCs secrete cytokines such as
interleukin-12 and interleukin-15, which upregulate both the
cytotoxic ability and cytokine production (IFN-g and tumor
necrosis factor-a) of NK cells. Concurrently, these proin-
flammatory cytokines induce DC maturation and the
subsequent activation of T cells, promoting a Th1-like
alloresponse. NKG2D has a critical role in the NK–DC
interaction, as MICA and MICB expression is upregulated on
DCs induced to mature by INF-a.29 Furthermore, cytokines
such as interleukin-2, interleukin-15, or IFN-a increase the
expression of NKG2D, and, consequently, the NKG2D-
mediated effector functions. In short, the NK–DC crosstalk
through interaction of NKG2D and NKG2D ligands con-
tributes to the feedback regulation of T-cell-mediated
immune responses.
After transplantation, IRI leads to a rapid upregulation of
NKG2D ligands that decreases within a few days. However, a
second phase of upregulation of NKG2D ligands was only
observed in allogenic transplantation,30 that is, Rag/ mice
(deficient in T and B cells but intact NK cells) fail to express
Rae-1 in the late phase, suggesting that the innate response is
insufficient to maintain the expression of these ligands after
the initial injury. These data suggest that initial interactions
of NKG2Dþ cells with its ligands amplify the adaptive
response, enhance the effector functions of CD8þ T cells
and NK cells, and increase graft injury. Blockade of NKG2D
significantly prolongs graft survival, prevents CD28-inde-
pendent rejection of cardiac allografts, and inhibits NK
effector functions without depleting NK cells or reducing
their migration to the graft. Prolonged treatment with anti-
NKG2D is critical in maintaining the blockage, as single doses
of monoclonal antibody were ineffective in the same cardiac
transplantation model.6 Activated NK cells after transplanta-
tion may be able to directly or indirectly provide T-cell
co-stimulatory signals that can promote allograft rejection.
In this way, the increased expression of NKG2D ligands in
transplanted allograft might recruit NK cells that directly
enhance the NKG2D-mediated cytotoxicity against the graft,
function as a bridge between innate and adaptive immunity,
and lead to the rejection of the graft.
IMMUNOSUPPRESSION AND NKG2D RECEPTOR
NK cells also have the ability to contribute to allograft
tolerance in patients who have undergone organ transplanta-
tion, through elimination or inhibition of donor DCs that
subsequently reduce the activation of alloreactive T cells or
modulate their response by immunosuppressants. Current
immunosuppression in solid organ transplantation involves
the use of pharmacological and biological agents that mainly
prevent the activation of T cells and development of immune
responses against the donor. However, the effects of
immunosuppressive agents on NK cells have not been clearly
defined.
Conflicting results on the influence of calcineurin
inhibitors on NK cell phenotype and function have been
recently reported. In vitro studies demonstrated that
cyclosporine and tacrolimus (FK506) produce dose-depen-
dent inhibition of NK cell degranulation and IFN-g
production.31 Moreover, blood samples from calcineurin
inhibitor-treated transplant patients show a reduction of NK
cell numbers and impaired effector functions. However, other
studies have reported that mycophenolic acid and rapamycin
inhibit the acquisition of NKG2A, reduce the expression of
NKG2D- and natural cytotoxicity receptor-activating recep-
tors, and lead to the loss of cytotoxicity against target
cells,32,33 but cyclosporine had no effects on the NK receptor
repertoire and leaves the cytolytic capacity intact.32,33 These
findings suggest that the distinct mechanisms of action of the
Kidney International Supplements (2011) 1, 52–57 55
B Sua´rez-A´lvarez et al.: NKG2D in solid organ rejection meet ing repor t
immunosuppressive reagents may contribute to their differ-
ential effects. As the effects of cyclosporine are known to be
reversible, the distinct experimental designs of these studies
may also contribute to the disparate results.
Kidney transplant patients receiving induction therapy
with polyclonal rabbit anti-thymocyte globulin showed
normal levels of NK cells at 1 month after transplantation,
but the repertoire of NK cell receptors was modified.34 These
cells had an increased expression of the inhibitory receptor
NKG2A, and reduced expression of killer Ig-like receptors
and NKG2D. The global functions of NK cells were not
affected and probably were maintained by a compensatory
effect of other receptors. The low levels of NKG2D during the
first months after transplantation are of special interest
because this receptor is involved in the adaptive immune
response against cytomegalovirus (CMV) infection, one of
the most common viral complications following solid organ
transplantation. NK cells have an important role in the initial
stages of viral infections, especially when adaptive immunity
is not fully active or is damaged by the use of immunosup-
pressive therapy. NKG2D interacts with its ligand MICA,
which is upregulated in CMV-infected cells, and NKG2D
functions as a co-stimulatory molecule in the activation of
human CD4þ T lymphocytes against CMV.35 Hadaya et al.36
recently demonstrated an expansion of NKG2Dþ NK cell
population during acute CMV infection, and these NK cells
may have a role similar to that of CD4þ T cells. For
resolving CMV infections, it is essential to maintain a proper
number and function of NK cells during the early time points
after transplantation, and decipher how immunosuppression
may affect NK activity to minimize the risks.
CONCLUDING REMARKS
In summary, the finding that expression of NKG2D ligands is
induced by IRI injury during acute and chronic rejection and
the discovery of their interactions with their activating
receptor NKG2D open a new route of intervention for
improving the outcome of solid organ transplantation.
NKG2Dþ cells were found in kidney biopsies during acute
and chronic allograft dysfunction, and blockage of this
interaction prolonged the survival in skin and heart-
transplanted mice models. Moreover, immunosuppression
may influence NK cell functionality and the ability of NK
cells to resolve opportunistic viral infections in addition to
modulating DC and T-cell responses to the donor. In the
future, it is important to determine the in vivo effect of these
drugs on the repertoire of inhibitory and activating receptors,
such as NKG2D, and their modulation of the effector
functions of NK sub-populations. In conclusion, blockade
of NKG2D with monoclonal antibodies or soluble NKG2D
ligands can contribute to prevent the effector functions of
NKG2Dþ cells that participate in the innate and adaptive
immune response involved in rejection after transplantation.
The interaction of NKG2D–NKG2D ligands would be an
interesting target for the development of new therapeutic
strategies for transplantation.
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